L2P4 (TFA)

L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC50 of 46.4 μM[1].

12352209

EBV; Peptide-Drug Conjugates (PDCs)

Antibody-drug Conjugate/ADC Related; Anti-infection

Cancer-programmed cell death

Cancer

98.25

DMSO : 50 mg/mL (ultrasonic)

O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCSC)C(N[C@@H](C(C)C)C(N[C@@H](CC2=CC=CC=C2)C(NCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](NC(CCCCCNC([C@@H](NC(C[N+]3=CC=C(/C=C/C(C=C4)=CC=C4N(CC)CC)C=C3)=O)CS)=O)=O)CC5=CC=C(O)C=C5.OC(C(F)(F)F)=O.[Cl-].[x]

C93H138ClN25O16S2.xC2HF3O2

1961.83 (free base)

[1]Li X, et al., Biocompatible Porphyrin-Peptide Conjugates as Theranostic Agents Targeting the Epstein-Barr Virus. Chempluschem. 2022 Aug 10;87 (11) :e202200184.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10772A/L2P4-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported